New Possibilities of Diagnostics of Non-Alcoholic Fatty Liver Disease

Pirogova I Yu ¹,²*, Yakovleva SV², Neuimina Tatyana Valeryevna^1.3, Sinitsyn SP^2,4, Chulkov VS^2,5 and Shamaeva Tatyana Nikolaevna⁶

Received: August 03, 2018;   Published: August 09, 2018

DOI: 10.32474/CTGH.2018.01.000111

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

The aim of the study was to create a non-invasive model for diagnosing fibrosis and steatosis in non-alcoholic fatty liver disease. Materials and methods. The study included 183 patients with liver steatosis according to ultrasound of the liver. General clinical examination, verification of the stage of fibrosis and steatosis of the liver on the Fibroscan 502 TOUCH device with the CAP software was carried out. Results of the study. Fibrosteatotest ©, based on stigmas of inflammation activity, insulin resistance, lipid spectrum for the diagnosis of fibrosis and steatosis (diagnostic accuracy of more than 80% compared to the results of fibroscanning), is created by the method of discriminant analysis, which allows to identify patients with the 2nd and more stage of fibrosis and steatosis of the liver, who need medication.

Conclusions: The Fibrosteatotest © test allows for screening patients to identify the stages of fibrosis and steatosis of the liver that require drug therapy.

Keywords: Non-Alcoholic Fatty Liver Disease; Fibrosis and Steatosis of the Liver; Fibrosteatotest

Abstract| Introduction| Objective| Materials and Methods| Results of the Study| The Discussion of the Results| References|